In an editorial commentary on this clinical trial, Schuler and Gudjonsson suggest that the role of IL-33 in AD may be more critical in the initiation phase of inflammation rather than in sustaining chronic, ongoing inflammation [76]. This evidence concerns the gene IL33 and Alzheimer disease.